Literature DB >> 27065703

Peritoneal Metastases: Prevention and Treatment.

Paul H Sugarbaker1.   

Abstract

Colorectal cancer is a surgicaly curable disease. It requires multimodality of treatment in Localy advanced and metastatic disease. Molecular markers like RAS mutation has brought in change in the mangement of metastatic disease. Nearly 15 to 20 % presents with peritonieal surface metastasis. The debate continues with systomic vs Cyutoreductive surgery with are without HIPEC. This article highlights management of peritoneal metastasis with special reference to prevention and treatment.

Entities:  

Keywords:  Colorectal; Cytoreductive; HIPEC; Peritoneal surface

Year:  2016        PMID： 27065703      PMCID： PMC4818621          DOI： 10.1007/s13193-016-0493-5

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN： 0975-7651


  6 in total

1.  Peritoneum as the first-line of defense in carcinomatosis.

Authors:  Paul H Sugarbaker
Journal:  J Surg Oncol       Date:  2007-02-01       Impact factor: 3.454

2.  Pushing the envelope beyond a centimeter in rectal cancer: oncologic implications of close, but negative margins.

Authors:  Timothy L Fitzgerald; Jason Brinkley; Emmanuel E Zervos
Journal:  J Am Coll Surg       Date:  2011-08-19       Impact factor: 6.113

Review 3.  Definition of patients presenting a high risk of developing peritoneal carcinomatosis after curative surgery for colorectal cancer: a systematic review.

Authors:  Charles Honoré; Diane Goéré; Amine Souadka; Frédéric Dumont; Dominique Elias
Journal:  Ann Surg Oncol       Date:  2012-10-23       Impact factor: 5.344

4.  Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.

Authors:  O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat
Journal:  J Clin Oncol       Date:  2004-08-15       Impact factor: 44.544

5.  Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial.

Authors:  Hans-Joachim Schmoll; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Silke Hoersch; Karen Rittweger; Daniel G Haller
Journal:  J Clin Oncol       Date:  2015-08-31       Impact factor: 44.544

6.  Results of systematic second-look surgery in patients at high risk of developing colorectal peritoneal carcinomatosis.

Authors:  Dominique Elias; Diane Goéré; Daniela Di Pietrantonio; Valérie Boige; David Malka; Niaz Kohneh-Shahri; Clarisse Dromain; Michel Ducreux
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969
  6 in total
  2 in total

1.  Case Report: First in Human Online Adaptive MR Guided SBRT of Peritoneal Carcinomatosis Nodules: A New Therapeutic Approach for the Oligo-Metastatic Patient.

Authors:  Luca Boldrini; Angela Romano; Lorenzo Placidi; Gian Carlo Mattiucci; Giuditta Chiloiro; Davide Cusumano; Veronica Pollutri; Marco Valerio Antonelli; Luca Indovina; Maria Antonietta Gambacorta; Vincenzo Valentini
Journal:  Front Oncol       Date:  2020-12-15       Impact factor: 6.244

2.  Curative versus palliative treatments for colorectal cancer with peritoneal carcinomatosis: a systematic review and meta-analysis.

Authors:  Wenqiong Wu; Shipeng Yan; Xianzhen Liao; Haifang Xiao; Zhongxi Fu; Lizhang Chen; Jinsong Mou; Haibo Yu; Lian Zhao; Xiangguo Liu
Journal:  Oncotarget       Date:  2017-10-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.